Login
Companies $IVVD
$0.55 +$0.01 (2.27%) After hours
Invivyd, Inc. logo

Invivyd, Inc.

invivyd.com

What Do They Do?

Develops and commercializes antibody medicines to prevent and treat serious viral infections, including coronavirus, for vulnerable people and healthcare providers.

How Do They Make Money?

FY2025 revenue

Who Are Their Customers?

Customers purchase PEMGARDA through third-party specialty distributors, while a small number of infusion centers, healthcare providers and provider institutions buy directly from Invivyd; the product is shipped to care sites, which bill health plans.

Do Revenues Turn Into Profits?

No. It lost $52.5M in FY2025.

Operating income, FY2025
−104% of revenue
▲ +69% (Loss) vs FY2024 (−$176.9M, −697%)
Net income, FY2025
−98% of revenue
▲ +69% (Loss) vs FY2024 (−$169.9M, −669%)
Free cash flow, FY2025
−109% of revenue
▲ +66% (Loss) vs FY2024 (−$170.6M, −672%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +18%
vs $13.1M in Q3 FY2025
Net income
▼ −220% (Loss)
vs −$10.5M in Q3 FY2025
  • Sep 29, 2026 Invivyd reported positive LIBERTY results and plans a VYD2311 BLA submission The company plans to use DECLARATION and LIBERTY as the basis for a U.S. accelerated-approval application.
  • Aug 30, 2026 Marc Elia became CEO
  • Jul 23, 2026 Nasdaq notified Invivyd of a minimum-bid-price deficiency The stock remained listed; the company had until January 19, 2027 to regain compliance.
  • Jul 6, 2026 Invivyd received advance notice of PEMGARDA EUA termination

From a candidate to a commercial launch The earlier report centered on a coronavirus antibody candidate and described commercialization as a future possibility. The latest report describes PEMGARDA's U.S. commercial launch alongside clinical development of another coronavirus antibody.

Broader virus targets The earlier report discussed influenza among its potential targets. The latest discusses candidates for respiratory syncytial virus and measles alongside its coronavirus programs.

Who Do They Compete With?

Competes with AstraZeneca, Roche Pharmaceuticals, Merck, Pfizer Pharmaceuticals, Gilead, Genentech, Moderna, Pfizer-BioNTech, Novavax, GSK, and Sanofi

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support